Dr Reddy’s Laboratories gains on launching generic version of Sapropterin Dihydrochloride powder
On Wednesday, Dr Reddy’s Laboratories announced the launch of Sapropterin Dihydrochloride powder for oral solution, 100 mg.
Sapropterin Dihydrochloride powder for oral solution, 100 mg is the generic version of Kuvan (Sapropterin Dihydrochloride) powder for oral solution, 100 mg, USP, which has been approved by US Food & Drug Administration (USFDA). The company mentioned in the press release that its Sapropterin Dihydrochloride powder for oral solution is available in 100 mg unit dose packets in a 30-count carton.
Sapropterin Dihydrochloride is a phenylalanine hydroxylase activator that is used to reduce blood phenylalanine (Phe) levels in adult and pediatric patients from the age of one month and older with Hyperphenylalaninemia (HPA) due to Tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU). Sapropterin Dihydrochloride powder for oral solution is generally intended to be used in conjunction with a Phe-restricted diet.
Commenting on the launch, Marc Kikuchi, Chief Executive Officer, North America Generics, Dr Reddy’s Laboratories said, “We are pleased to launch this generic version of Sapropterin Dihydrochloride powder for oral solution, illustrating our continued commitment to bring affordable generic medicines to the market for patients. At the same time, this product demonstrates that we are actively expanding the breadth of our portfolio with a treatment for a rare disease.”
Dr Reddy’s Laboratories Ltd is an integrated pharmaceutical company offering a portfolio of products & services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.
On Wednesday, the stock of the company closed at Rs 4,684 per share, up by 1.44 per cent or Rs 66.45 per share. The 52-week high is Rs 5,514.65 while its 52-week low is Rs 3,200 on BSE.